Is Wegovy a GLP-1? How Semaglutide Works and What It Contains

If you have searched for Wegovy, you have probably seen the term “GLP-1” used alongside it. But are Wegovy, semaglutide and GLP-1 actually the same thing?

Not quite.

Wegovy is a medicine that contains semaglutide. Semaglutide is a GLP-1 receptor agonist, which means it is designed to act on the same receptor as the naturally occurring hormone GLP-1. Wegovy does not contain the body’s natural GLP-1 hormone.

That distinction is useful when you are comparing weight-management medicines because some treatments act on more than one hormone pathway. Wegovy works through the GLP-1 receptor, while medicines such as tirzepatide act on both GIP and GLP-1 receptors.

There is also a newer development to know about. In June 2026, the MHRA authorised an oral Wegovy formulation containing semaglutide for weight management in the UK. This means Wegovy is no longer limited to an injectable format in the UK.

This guide explains what Wegovy contains, what GLP-1 means, how semaglutide works, how it differs from GIP and what the new tablet means for people considering treatment.

Key things to know

• Wegovy contains the active ingredient semaglutide.
• Semaglutide is a GLP-1 receptor agonist.
• GLP-1 is a naturally occurring hormone in the body.
• Wegovy does not contain natural GLP-1.
• Semaglutide acts on the GLP-1 receptor and mimics some of the effects of GLP-1.
• Wegovy is not a dual GIP and GLP-1 receptor agonist.
• GIP and GLP-1 are different hormone signalling pathways.
• Wegovy is available as an injectable medicine and, following the 2026 UK authorisation, as an oral formulation.
• The tablet and injection should not be switched without appropriate prescribing advice.
• Whether Wegovy is suitable depends on individual clinical assessment.

Is Wegovy a GLP-1 Medicine?

Yes. Wegovy is a GLP-1 receptor agonist medicine because it contains semaglutide.

NICE lists semaglutide among the medicines used for weight management and identifies it as a GLP-1 receptor agonist. The term “GLP-1 medicine” is often used as a shorter way of describing this type of treatment, although “GLP-1 receptor agonist” is more precise.

So, if someone asks, “Is Wegovy a GLP-1?”, the simple answer is yes.

If they ask whether Wegovy literally contains the GLP-1 hormone, the answer is no.

What Does GLP-1 Mean?

GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally produced by the body, including after eating.

GLP-1 is involved in several processes, including blood glucose regulation and appetite signalling. GLP-1 receptor agonists are medicines that activate the GLP-1 receptor and mimic some of the effects of the natural hormone.

Semaglutide is one of these medicines. It is not the same substance as the GLP-1 hormone itself.

That is why “GLP-1 receptor agonist” is a more accurate description than saying that Wegovy contains GLP-1.

Does Wegovy Contain GLP-1?

No. Wegovy does not contain the naturally occurring GLP-1 hormone.

The active ingredient in Wegovy is semaglutide. Semaglutide acts on the GLP-1 receptor, which allows it to mimic some of the effects of GLP-1 in the body.

A simple way to remember the difference is:

GLP-1 = a naturally occurring hormone

Semaglutide = the active medicine that acts on the GLP-1 receptor

Wegovy = the medicinal product containing semaglutide

This difference may sound small, but it helps avoid confusion when comparing medicines and reading information about GLP-1 treatment.

How Does Semaglutide Work?

Semaglutide activates GLP-1 receptors in the body. These receptors are involved in blood glucose regulation, appetite and feelings of fullness.

As part of weight management, semaglutide can affect appetite and food intake. It can also delay gastric emptying, particularly earlier in treatment. This can contribute to feeling fuller for longer.

Wegovy is not a medicine that directly “burns” or “melts” body fat. Its effect on weight is linked to the way semaglutide changes appetite and energy intake as part of a wider weight-management plan.

NICE recommends weight-management medicines alongside a reduced-calorie diet and increased physical activity.

Does Wegovy Have GIP?

No. Wegovy does not act as a GIP receptor agonist.

Its active ingredient, semaglutide, is a GLP-1 receptor agonist. This is different from tirzepatide, which acts on both GIP and GLP-1 receptors.

GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it is a naturally occurring hormone involved in metabolic signalling, but it is a different hormone and acts through a different receptor.

So, when comparing Wegovy with a medicine such as Mounjaro, it is useful to look at the active ingredient and the receptors it acts on rather than grouping all of these medicines together as simply “GLP-1s”.

Why Is the Difference Between GLP-1 and GIP Important?

The words GLP-1 and GIP can easily become confusing because both are discussed in weight management and diabetes treatment.

However, they are not interchangeable terms.

A GLP-1 receptor agonist is designed to activate the GLP-1 receptor. A dual GIP and GLP-1 receptor agonist acts on both pathways.

This difference is important when you are reading about medicines because two treatments can be used for similar conditions while having different active ingredients and mechanisms.

For example, Wegovy contains semaglutide, while Mounjaro contains tirzepatide. Semaglutide acts as a GLP-1 receptor agonist, whereas tirzepatide acts on both GIP and GLP-1 receptors.

These key differences also matter when discussing any weight loss medication. Wegovy is authorised for weight management, while Ozempic is a semaglutide product authorised for type 2 diabetes. Having the same active ingredient does not automatically mean that two products have the same approved use.

Is There a Wegovy GLP-1 Pill in the UK?

Yes. This is one of the important changes to Wegovy treatment in the UK in 2026.

On 11 June 2026, the MHRA authorised an oral semaglutide formulation of Wegovy for weight loss and weight management in eligible adults. It became the UK's first GLP-1 receptor agonist tablet authorised specifically for weight management.

The tablet is still a prescription medicine. It is not an over-the-counter version of Wegovy.

The authorisation also means that older information saying that Wegovy is only available as an injection may no longer be up to date for the UK.

The active ingredient remains semaglutide, so the oral formulation is still a GLP-1 receptor agonist.

Is the Wegovy Pill the Same as the Injection?

The oral and injectable Wegovy formulations contain the same active ingredient, semaglutide, but they are different formulations with different administration instructions.

That does not mean you should switch between them yourself.

The MHRA's 2026 announcement gives specific dosing information for the newly authorised tablet, and the injectable product has its own dosing schedule. Your prescriber or another appropriate healthcare professional should decide which formulation is suitable for you.

If you are already using Wegovy injection and are interested in the tablet, speak to your prescriber rather than changing your treatment yourself.

Does the New Tablet Mean Wegovy Is No Longer an Injection?

No.

Wegovy continues to be available as an injectable formulation. The 2026 authorisation simply means that an oral semaglutide formulation is now also authorised for weight management in the UK.

So, instead of thinking of Wegovy as “the injection”, it is more accurate to think of Wegovy as a semaglutide medicine that is available in different authorised formulations.

The exact formulation and dosing instructions still matter.

Does Wegovy Work Only Through GLP-1?

Semaglutide is classified as a GLP-1 receptor agonist, and its direct receptor activity is through the GLP-1 receptor.

This is different from dual agonists such as tirzepatide, which act on both GIP and GLP-1 receptors.

It is therefore accurate to describe Wegovy as a GLP-1 receptor agonist rather than a GIP and GLP-1 medicine.

Is Wegovy a Single-Pathway GLP-1 Medicine?

In simple terms, yes. Wegovy can be described as a GLP-1 receptor agonist rather than a dual GIP and GLP-1 receptor agonist.

The phrase “single-pathway” can help explain the difference, but the more medically accurate term is “GLP-1 receptor agonist”.

What matters is that semaglutide acts at the GLP-1 receptor. It does not have the additional GIP receptor activity associated with tirzepatide.

Does Wegovy Contain Semaglutide?

Yes. Semaglutide is the active ingredient in Wegovy.

It can help to separate the three terms:

Wegovy = the brand and medicinal product

Semaglutide = the active ingredient

GLP-1 receptor agonist = the type of medicine

This is why someone can correctly say that Wegovy is a GLP-1 medicine while also saying that it does not contain the body's natural GLP-1 hormone.

Is Semaglutide the Same as GLP-1?

No. Semaglutide and GLP-1 are not the same substance.

GLP-1 is a naturally occurring hormone. Semaglutide is a medicine that activates the GLP-1 receptor and mimics some of the hormone's effects.

This distinction is particularly useful when reading about medicines online. “GLP-1” may refer to the hormone, the receptor pathway or, more generally, a group of medicines that act on the GLP-1 receptor.

Semaglutide belongs to that medicine group, but it is not the natural hormone itself.

Why Does Wegovy Affect Appetite?

GLP-1 receptors are involved in appetite signalling and feelings of fullness. By activating these receptors, semaglutide can affect appetite and food intake.

Some people taking Wegovy may notice that they feel full sooner or have less interest in food. However, individual experiences can differ.

If you have another health condition, take other medicines or have concerns about changes in appetite, these are worth discussing with your prescriber. Weight-management treatment should take your wider health and circumstances into account rather than focusing on weight alone.

Does Wegovy Work Without Dietary Changes?

Wegovy is not intended to replace dietary and physical activity support.

NICE recommends weight-management medicines alongside a reduced-calorie diet and increased physical activity. It also recognises that weight management should take individual circumstances and health needs into account.

This does not mean you need to follow a rigid diet or make every change at once. Your healthcare professional can help you understand what approach is appropriate for you.

It is also possible for weight to change again after stopping weight-management medicine. This is why ongoing support and a plan for maintaining weight are important parts of treatment. NICE recommends offering support to people who are stopping weight-management medicines.

Is Wegovy a Weight-Loss Hormone?

No. Wegovy is a medicine, not a naturally occurring hormone.

Its active ingredient, semaglutide, acts on the GLP-1 receptor and mimics some of the effects of GLP-1.

Calling Wegovy a “weight-loss hormone” can therefore make the medicine sound more complicated than it is. A clearer description is that Wegovy contains semaglutide, a GLP-1 receptor agonist used for weight management in eligible people.

Does Wegovy Contain GIP as an Ingredient?

No. GIP is not the active ingredient in Wegovy.

Wegovy contains semaglutide. Semaglutide acts on the GLP-1 receptor and is not a GIP receptor agonist.

This is different from tirzepatide, which acts on both GIP and GLP-1 receptors.

So, if you see Wegovy described online as a “GIP and GLP-1” medicine, check the source carefully. The two medicines should not be given the same pharmacological description.

Can Wegovy Be Called a Dual Agonist?

No. Wegovy is not classified as a dual GIP and GLP-1 receptor agonist.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide, by comparison, acts on both GIP and GLP-1 receptors.

Using the correct terms helps you understand what a medicine actually does and avoids making different treatments sound interchangeable when they are not.

Does Wegovy GLP-1 Treatment Come as a Tablet and Injection?

Yes. In the UK, Wegovy is now authorised as both an injectable and an oral semaglutide formulation for weight management. The oral formulation was authorised by the MHRA on 11 June 2026.

The two formulations are not simply different ways of taking exactly the same dose. Their dosing schedules and instructions differ, so the product information for the formulation being prescribed should be followed.

If you are considering moving from an injection to a tablet, discuss it with your prescriber first.

Is Wegovy GLP-1 Pill Treatment Over the Counter?

No. The Wegovy tablet is still a prescription medicine.

The MHRA authorised the oral semaglutide formulation for weight management in eligible adults, but this does not mean that it can be bought without a prescription. Appropriate clinical assessment and prescribing safeguards still apply.

If you see websites offering prescription medicines without appropriate checks, be cautious. The MHRA, ASA and GPhC have specifically warned businesses about the promotion and supply of newly authorised and unlicensed weight-management medicines.

Can You Choose Wegovy Tablets Instead of Injections?

If both formulations are clinically appropriate for you, your preference can be discussed with your prescriber.

However, the decision should not be based only on whether you prefer a tablet or injection. Your medical history, other medicines, treatment suitability and the instructions for the specific formulation all matter.

If you are already using Wegovy injection and would prefer tablets, speak to the healthcare professional managing your treatment before making a change.

Are Wegovy Tablets Easier Than Injections?

That depends on the person.

Some people may prefer a tablet because they do not want to inject themselves. Others may find an injectable routine easier to manage.

The oral formulation also has its own administration instructions, so “tablet” does not automatically mean “easier” for everyone.

The important point is to choose the formulation that is clinically suitable for you and follow its specific instructions.

Can You Switch From Wegovy Injection to Wegovy Pill Yourself?

No. Do not change between prescription formulations without appropriate medical advice.

Although both formulations contain semaglutide, their dosing schedules and administration instructions are different.

The MHRA has published specific dosing information for the new oral formulation. This means switching should be based on the approved product information and your individual treatment plan rather than simply matching the dose you were using with an injection.

If you are thinking about changing formulation, ask your prescriber or pharmacist how the change should be managed.

Is Wegovy More Effective Because It Is a GLP-1?

Being a GLP-1 receptor agonist tells you how Wegovy works. It does not, by itself, tell you how much weight an individual person will lose.

Clinical trials of semaglutide have shown meaningful weight reduction in some groups of people, but trial results are averages from specific study populations. They should not be treated as a prediction of what will happen to one person.

Your response can be affected by factors such as your health, other medicines, treatment adherence and how your body responds to the medicine.

NICE also recommends reviewing treatment response rather than assuming that everyone will benefit in the same way. For semaglutide, NICE says treatment can be considered for stopping if less than 5% of initial weight has been lost after 6 months of treatment.

Does Wegovy Guarantee Weight Loss?

No. Wegovy cannot guarantee a particular amount of weight loss.

Clinical studies report average results, but an average does not tell you exactly what will happen to you. Some people lose more weight, some lose less, and some may need their treatment reviewed.

It is also important not to compare yourself with another person's result. Their starting weight, health, treatment plan and response to medicine may be very different from yours.

If you are considering Wegovy, the more useful question is whether it is appropriate for you and whether your response can be monitored safely over time.

How Is Wegovy Different From a GIP and GLP-1 Medicine?

The main difference is the receptor pathway involved.

Wegovy contains semaglutide, which acts as a GLP-1 receptor agonist. A medicine such as tirzepatide acts on both the GIP and GLP-1 receptors.

That does not mean one type is automatically suitable for everyone. Different medicines have different prescribing criteria, dosing instructions, safety considerations and approved uses.

This is why it is useful to look at the active ingredient and mechanism rather than simply referring to every weight-management medicine as a “GLP-1”.

Why Does Correct Classification Matter?

It is easy to see why the terms become confusing. GLP-1, semaglutide, Wegovy and GIP are often mentioned together in articles, social media posts and discussions about weight management.

But they describe different things.

GLP-1 is a naturally occurring hormone.

Semaglutide is an active medicine that acts on the GLP-1 receptor.

Wegovy is a medicinal product containing semaglutide.

GIP is a different hormone involved in another signalling pathway.

Keeping these terms separate makes it easier to understand what a medicine contains, how it works and how it differs from other treatments.

What Should You Check Before Starting Wegovy?

Wegovy is not suitable for everyone, so a prescription should follow an appropriate clinical assessment.

For adults, this can include looking at BMI, weight-related health conditions, other medicines, medical history and the person's wider circumstances. NICE also recommends lower BMI thresholds in certain ethnic groups because health risks associated with BMI can occur at lower levels in some populations.

The authorised use of Wegovy can also depend on age and the specific product and indication. The 2026 oral Wegovy authorisation, for example, applies to adults with obesity or adults who are overweight with at least one weight-related health condition.

There are also situations where semaglutide should not be used or where extra care is needed. Your prescriber will consider these before recommending treatment.

If you have a health condition or take other medicines, tell your prescriber. This helps them assess whether Wegovy is an appropriate option and whether any additional monitoring is needed.

Does Wegovy Need Ongoing Review?

Yes. Starting Wegovy is not the end of the assessment.

Follow-up can look at how well the treatment is working, whether you are experiencing side effects and whether it remains appropriate to continue. NICE recommends reviewing weight-management medicines as part of ongoing care rather than treating the first prescription as a permanent decision.

Common side effects of semaglutide include gastrointestinal symptoms such as nausea, vomiting, diarrhoea and constipation. These can be more noticeable when the dose is increased.

More serious problems can also occur, although they are not the same as the common side effects. For example, severe and persistent abdominal pain can be a sign of acute pancreatitis and needs urgent medical assessment.

Your healthcare professional can also review other medicines and health conditions that may affect treatment. If you develop new or worrying symptoms while taking Wegovy, seek appropriate medical advice rather than assuming they are a normal part of treatment.

Medical Disclaimer

Wegovy is a prescription weight-management medicine containing semaglutide, a GLP-1 receptor agonist. It does not contain the body's natural GLP-1 hormone and is not a dual GIP and GLP-1 receptor agonist.

This guide is for general information about Wegovy, semaglutide, GLP-1, GIP and the oral and injectable formulations available in the UK. It does not provide personalised prescribing, dosing or switching advice and does not replace advice from a qualified healthcare professional.